Search results for " type 2"

showing 10 items of 761 documents

Autophagy, cathepsin L transport, and acidification in cultured rat fibroblasts.

1992

The mechanisms of enzyme delivery to and acidification of early autophagic vacuoles in cultured fibroblasts were elucidated by cryoimmunoelectron microscopic methods. The cation-independent mannose-6-phosphate receptor (MPR) was used as a marker of the pre-lysosomal compartment, and cathepsin L and an acidotropic amine (3-(2,4-dinitroanilino)-3'-amino-N-methyl-dipropylamine (DAMP), a cytochemical probe for low-pH organelles) as markers of both pre-lysosomal and lysosomal compartments. In addition, cationized ferritin was used as an endocytic marker. In ultrastructural double labeling experiments, the bulk of all the antigens was found in vesicles containing tightly packed membrane material…

HistologyCathepsin LEndocytic cycleFluorescent Antibody TechniqueReceptors Cell SurfaceVacuoleReceptor IGF Type 2Cathepsin LEndopeptidasesOrganelleAutophagyAnimalsMicroscopy ImmunoelectronCells CulturedCathepsinMannosephosphatesbiologyVesicleBiological TransportFibroblastsHydrogen-Ion ConcentrationCathepsinsRatsCell biologyFerritinCysteine EndopeptidasesDinitrobenzenesBiochemistryCytoplasmbiology.proteinAnatomyJournal of Histochemistry & Cytochemistry
researchProduct

Enlarged PLIN5-uncoated lipid droplets in inner regions of skeletal muscle type II fibers associate with type 2 diabetes

2022

Skeletal muscle physiology remains of paramount importance in understanding insulin resistance. Due to its high lipid turnover rates, regulation of intramyocellular lipid droplets (LDs) is a key factor. Perilipin 5 (PLIN5) is one of the most critical agents in such regulation, being often referred as a protector against lipotoxicity and consequent skeletal muscle insulin resistance. We examined area fraction, size, subcellular localization and PLIN5 association of LDs in two fiber types of type 2 diabetic (T2D), obese (OB) and healthy (HC) individuals by means of fluorescence microscopy and image analysis. We found that T2D type II fibers have a significant sub-population of large and inter…

Histologylipid dropletsMuscle Fibers SkeletalSkeletal musclelihaksetlipiditPerilipin-5Type II diabetesSDG 3 - Good Health and Well-beinginsulin resistanceHumansskeletal muscleMuscle SkeletalInsulin resistanceCell BiologyGeneral MedicineLipid MetabolismLipid dropletsinsuliiniresistenssifiber typePLIN5Diabetes Mellitus Type 2/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingproteiinitFiber typeaikuistyypin diabetes
researchProduct

Association between use of novel glucose-lowering drugs and COVID-19 hospitalization and death in patients with type 2 diabetes: a nationwide registr…

2022

Abstract Aims Type 2 diabetes (T2DM) in patients with coronavirus disease-19 (COVID-19) is associated with a worse prognosis. We separately investigated the associations between the use of sodium-glucose cotransporter 2 inhibitors (SGLT2i), glucagon-like peptide-1 receptor agonists (GLP-1 RA), and dipeptidyl peptidase-4 inhibitors (DPP-4i), and the risk of COVID-19 hospitalization and death. Methods and results Patients with T2DM registered in the Swedish National Patient Registry and alive on 1 February 2020 were included. ‘Incident severe COVID-19’ was defined as the first hospitalization and/or death from COVID-19. A modified Poisson regression approach was applied to a 1:1 propensity sc…

HospitalizationDipeptidyl-Peptidase IV InhibitorsGlucoseDiabetes Mellitus Type 2Glucagon-Like Peptide 1COVID-19 Dipeptidyl peptidase-4 inhibitors (DPP-4i) Glucagon-like peptide-1 receptor agonists Hospitalization Mortality Sodium-glucose cotransporter 2 inhibitorsHumansCOVID-19Pharmacology (medical)RegistriesCardiology and Cardiovascular MedicineGlucagon-Like Peptide-1 Receptor
researchProduct

The Emerging Role of the Endocannabinoid System in Endocrine Regulation and Energy Balance

2005

During the last few years, the endocannabinoid system has emerged as a highly relevant topic in the scientific community. Many different regulatory actions have been attributed to endocannabinoids, and their involvement in several pathophysiological conditions is under intense scrutiny. Cannabinoid receptors, named CB1 receptor and CB2 receptor, first discovered as the molecular targets of the psychotropic component of the plant Cannabis sativa, participate in the physiological modulation of many central and peripheral functions. CB2 receptor is mainly expressed in immune cells, whereas CB1 receptor is the most abundant G protein-coupled receptor expressed in the brain. CB1 receptor is expr…

Hypothalamo-Hypophyseal Systemmedicine.medical_specialtyCannabinoid receptorEndocrinology Diabetes and Metabolismmedicine.medical_treatmentmedia_common.quotation_subjectPituitary-Adrenal SystemEndocrine SystemBiologyEndocrinologyInternal medicineCannabinoid Receptor ModulatorsmedicineCannabinoid receptor type 2ACID AMIDE HYDROLASEAnimalsHumansEndocrine systemMESSENGER-RNA EXPRESSIONVAGAL AFFERENT NEURONSObesityReceptors CannabinoidReceptorCannabinoid Receptor Antagonistsmedia_commonmusculoskeletal neural and ocular physiologyACTIVATED PROTEIN-KINASECENTRAL-NERVOUS-SYSTEMDISTINCT NEURONAL SUBPOPULATIONSAppetiteEndocannabinoid systemCANNABINOID CB1 RECEPTORCORTICOTROPIN-RELEASING-FACTOREndocrinologynervous systemCannabinoid receptor antagonistlipids (amino acids peptides and proteins)PITUITARY-ADRENAL AXISPREIMPLANTATION MOUSE EMBRYOCannabinoidEnergy MetabolismNeurosciencepsychological phenomena and processesEndocannabinoidsEndocrine Reviews
researchProduct

Epidemiological approach of type 2 myocardial infarction : Etiologies, characteristics, treatment and prognosis.

2020

Introduction: Type 2 Myocardial infarction (MI)has been recently defined as an imbalance between oxygen supply and demand, in the absence of atherothromthrombosis. This work aimed to describe the main etiolgies as well as epidemiological, clinical and prognostic characteristics.Method: Data from patients with type 2 MI were collected from the RICO cohort (Observatoire des Infarctus de Cote d'Or). In a complementary work, we analyzed the retrospective data of the emergency department of Dijon University Hospital.Results: Among 4,436 consecutive patients hospitalized for MI in Dijon emergency department over 3 years, 947 (21%) had type 2 MI (median age: 81 years). In the RICO cohort, 4,572 co…

Infactus du myocardeÉpidémiologieMyocardial infarctionEtiologies[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologyÉtiologiesEpidemiologyTyoe 2 myocardial infarctionInfarctus de type 2PronosticPrognosis[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct

Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group

2011

Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in females, with a high prevalence. The etiology of this heterogeneous condition remains obscure, and its phenotype expression varies. Two widely cited previous ESHRE/ASRMsponsored PCOS consensus workshops focused on diagnosis (published in 2004) and infertility management (published in 2008), respectively. The present third PCOS consensus report summarizes current knowledge and identifies knowledge gaps regarding various women's health aspects of PCOS. Relevant topics addressed-all dealt with in a systematic fashion-include adolescence, hirsutism and acne, contraception, menstrual cycle abnormalities, quality of life, e…

Infertilitymedicine.medical_specialtyConsensusMEDLINEmetabolic syndromeSettore MED/13 - EndocrinologiaPolycystic Ovary Syndrome Adolescence Metabolism Cardiovascular riskMetabolic DiseasesQuality of lifeSDG 3 - Good Health and Well-beingPregnancyRisk Factorscardiovascular diseaseNeoplasmsinsulin resistancemedicineHumanscancerPolycystic ovary syndromehirsutismhirsutismGynecologybiologypregnancy complicationsbusiness.industryPolycystic ovary syndrome (PCOS)cancer; cardiovascular disease; contraception; hirsutism; insulin resistance; metabolic syndrome; Polycystic ovary syndrome; pregnancy complications; quality of life; type 2 diabetesObstetrics and GynecologyAnti-Müllerian hormonemedicine.diseasePolycystic ovarycontraceptionquality of lifeReproductive MedicineCardiovascular DiseasesFamily medicinebiology.proteinEtiologyFemaletype 2 diabetesbusinessInfertility Female
researchProduct

Post-COVID syndrome, inflammation, and diabetes

2022

The raging COVID-19 pandemic is in its third year of global impact. The SARS CoV 2 virus has a high rate of spread, protean manifestations, and a high morbidity and mortality in individuals with predisposing risk factors. The pathophysiologic mechanisms involve a heightened systemic inflammatory state, cardiometabolic derangements, and varying degrees of glucose intolerance. The latter can be evident as significant hyperglycemia leading to new -onset diabetes or worsening of preexisting disease. Unfortunately, the clinical course beyond the acute phase of the illness may persist in the form of a variety of symptoms that together form the so-called "Long COVID" or "Post-COVID Syndrome". It i…

InflammationEndocrinologyCOVID-19 Long COVID New-onset diabetes Newly diagnosed diabetes Post-COVID syndrome SARS CoV-2 Syndemia Type 2 diabetesSARS-CoV-2Endocrinology Diabetes and MetabolismHyperglycemiaInternal MedicineDiabetes MellitusHumansCOVID-19RNA ViralPandemics
researchProduct

Association of Dietary Patterns with MRI Markers of Hepatic Inflammation and Fibrosis in the MAST4HEALTH Study

2022

Whereas the etiology of non-alcoholic fatty liver disease (NAFLD) is complex, the role of nutrition as a causing and preventive factor is not fully explored. The aim of this study is to associate dietary patterns with magnetic resonance imaging (MRI) parameters in a European population (Greece, Italy, and Serbia) affected by NAFLD. For the first time, iron-corrected T1 (cT1), proton density fat fraction (PDFF), and the liver inflammation fibrosis score (LIF) were examined in relation to diet. A total of 97 obese patients with NAFLD from the MAST4HEALTH study were included in the analysis. A validated semi-quantitative food frequency questionnaire (FFQ) was used to assess the quality of diet…

InflammationHealth Toxicology and MutagenesisPublic Health Environmental and Occupational HealthRNASHdietary patternsFibrosisMagnetic Resonance ImagingNAFLD; NASH; MRI; dietary patterns; MAST4HEALTHArticleDiabetes Mellitus Type 2LiverNon-alcoholic Fatty Liver DiseaseNAFLDMAST4HEALTHHumansMedicineMRI
researchProduct

Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes.

2017

BACKGROUND Degludec is an ultralong-Acting, once-daily basal insulin that is approved for use in adults, adolescents, and children with diabetes. Previous open-label studies have shown lower day-To-day variability in the glucose-lowering effect and lower rates of hypoglycemia among patients who received degludec than among those who received basal insulin glargine. However, data are lacking on the cardiovascular safety of degludec. METHODS We randomly assigned 7637 patients with type 2 diabetes to receive either insulin degludec (3818 patients) or insulin glargine U100 (3819 patients) once daily between dinner and bedtime in a double-blind, treat-To-Target, event-driven cardiovascular outco…

Insulin degludecBlood GlucoseMalemedicine.medical_treatmentDEVOTE Study GroupInsulin GlargineType 2 diabetesKaplan-Meier Estimate030204 cardiovascular system & hematologylaw.inventiondiabetes ; insulin0302 clinical medicineRandomized controlled triallawCardiovascular DiseaseGLUCOSE CONTROL11 Medical and Health SciencesRISKCOMPLICATIONSOUTCOMESIncidenceGeneral MedicineMiddle AgedInsulin Long-ActingVARIABILITYCardiovascular Diseasesdiabetes mellitusFemaleLife Sciences & BiomedicineHumanmedicine.drugmedicine.medical_specialty030209 endocrinology & metabolismAged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus Type 2; Double-Blind Method; Female; Humans; Hypoglycemia; Hypoglycemic Agents; Incidence; Insulin Glargine; Insulin Long-Acting; Kaplan-Meier Estimate; Male; Middle Aged; Medicine (all)HypoglycemiaBedtimeArticleEVENTS03 medical and health sciencesHYPOGLYCEMIAMedicine General & InternalDouble-Blind MethodInternal medicineDiabetes mellitusGeneral & Internal MedicinemedicineHumansHypoglycemic AgentsIntensive care medicineMETAANALYSISAgedScience & TechnologyHypoglycemic AgentInsulin glarginebusiness.industryInsulinmedicine.diseaseDiabetes Mellitus Type 2businessBASAL INSULIN
researchProduct

Insulin degludec and insulin glargine 300 U/mL: Which of these two insulins causes less hypoglycemia?

2019

The interesting article by Yamabe et al.1 showed, using continuous glucose monitoring, that insulin degludec (I‐Deg) was associated with a high percentage of time with nocturnal hypoglycemia than with insulin glargine 300 U/mL (I‐G300; P = 0.02). However, we observe that some possible confounding factors might have influenced the results, such as differences in concomitant medications, use of the same titration protocol for both kinds of insulin or differences in glucose levels. This is also a recurrent problem in clinical trials, which sometime produce conflicting results. In fact, the study of Yamabe et al. is partly in agreement with some recently published clinical trials that gave diff…

Insulin degludecBlood Glucosemedicine.medical_specialtyendocrine system diseasesEndocrinology Diabetes and Metabolismmedicine.medical_treatmentdiabetes insulin clinical trials hypoglicemiaInsulinsInsulin GlargineHypoglycemiaDiseases of the endocrine glands. Clinical endocrinologyInternal medicineDiabetes mellitusInternal MedicinemedicineHumansHypoglycemic AgentsLetters to the EditorLetter to the EditorGlycated HemoglobinInsulin glarginebusiness.industryInsulinBlood Glucose Self-Monitoringnutritional and metabolic diseasesGeneral Medicinemedicine.diseaseRC648-665HypoglycemiaClinical trialInsulin Long-ActingEndocrinologyDiabetes Mellitus Type 2businessmedicine.drug
researchProduct